A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Astellas Pharma Inc
Therapeutic Advances in Childhood Leukemia Consortium
Center for International Blood and Marrow Transplant Research
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
Arog Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
University of Nebraska
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Eastern Cooperative Oncology Group
University of Washington
M.D. Anderson Cancer Center
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
M.D. Anderson Cancer Center
Virginia Commonwealth University
University of Washington
University of Washington
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Dartmouth-Hitchcock Medical Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
PETHEMA Foundation
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Washington University School of Medicine
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
University of Wisconsin, Madison
Nohla Therapeutics, Inc.
National Cancer Institute (NCI)
Cellerant Therapeutics
University of Washington
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
PETHEMA Foundation
Washington University School of Medicine
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
Cellerant Therapeutics
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Washington University School of Medicine
National Cancer Institute (NCI)
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
University Hospital Muenster
M.D. Anderson Cancer Center